Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326017 | 0.81 | CHRM3 (0.41) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28669857 | 0.72 | AKR1C3 (0.44) | AKR1C3AKR1C1GRIN2B | |
| SCHEMBL23870966 | 0.71 | CHRNA7 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL24325941 | 0.71 | CYP19A1 (0.31) | — | |
| SCHEMBL30457857 | 0.71 | LMNA (0.44) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26358045 | 0.71 | CHRM3 (0.43) | CHRM3AKR1C3AKR1C1 | |
| SCHEMBL1623586 | 0.70 | CHRNA7 (0.61) | MEN1KMT2A | |
| SCHEMBL1623587 | 0.70 | CHRNA7 (0.61) | MEN1KMT2A | |
| SCHEMBL26358036 | 0.70 | RIPK1 (0.45) | CHRM3AKR1C3AKR1C1 | |
| SCHEMBL25223711 | 0.69 | KDM1A (0.43) | CHRM3HCRTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CHRM3 3877/4885CHRM2 4445/4885CHRM1 4247/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CHRM3 3877/4885CHRM2 4445/4885CHRM1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.